Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IWWM-11 2022 | The role of chemoimmunotherapy in Waldenström’s macroglobulinemia

Jorge Castillo • 28 Oct 2022
IWWM-11 2022
Lymphoma Non-Hodgkin Lymphoma Rare Diseases Waldenström’s Macroglobulinemia

In this video, Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, briefly summarizes the role of chemoimmunotherapy in Waldenström’s macroglobulinemia (WM) in the era of novel targeted agents, and highlights the importance of combination approaches. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consulting fees or research funds from Abbvie, AstraZeneca, BeiGene, Casma, Cellectar, Janssen, Pharmcyclics, Roche, TG Therapeutics.

More from Jorge Castillo

2:22
Real-world outcomes following dose reduction of first-line ibrutinib in patients with WM
Jorge Castillo • 10 Dec 2023
2:27
Acalabrutinib plus rituximab for treating anti-MAG mediated IgM peripheral neuropathy in WM
Jorge Castillo • 10 Dec 2023
3:03
Outcomes following venetoclax monotherapy in patients with R/R WM in the real-world setting
Jorge Castillo • 10 Dec 2023
3:32
Research updates in WM from ASH 2023
Jorge Castillo • 10 Dec 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals